Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

New application of n-butanol-2-o-(l-pyroglutamic acid-n-6-)-α-d-fructofuranoside

A technology of -N-6-, fructofuranoside, which is applied in the new application field of n-butanol-2-O--α-D-fructofuranoside, can solve the problem of improving the mechanism of AD that cannot delay the development of the disease Insufficient in-depth, unable to verify the effect of drug treatment and other issues

Active Publication Date: 2021-09-21
HEILONGJIANG UNIV OF CHINESE MEDICINE
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] At present, there are 5 anti-AD drugs approved for marketing in the world, namely donepezil, rivastigmine, galantamine, memantine, and donepezil+memantine compound preparations. Mechanisms to improve AD symptoms, not delay disease progression
[0004] In addition, the research on the mechanism of improvement of AD by existing drugs is not deep enough, and it is impossible to verify that the drug has a therapeutic effect from the perspective of molecular biology

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • New application of n-butanol-2-o-(l-pyroglutamic acid-n-6-)-α-d-fructofuranoside
  • New application of n-butanol-2-o-(l-pyroglutamic acid-n-6-)-α-d-fructofuranoside
  • New application of n-butanol-2-o-(l-pyroglutamic acid-n-6-)-α-d-fructofuranoside

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0041] In order to make the object, technical solution and advantages of the present invention clearer, the present invention will be further described in detail below in conjunction with the accompanying drawings and embodiments. The specific embodiments described here are only used to explain the present invention, not to limit the present invention.

[0042] The new application of n-butanol-2-O-(L-pyroglutamic acid-N-6-)-α-D-fructofuranoside specifically includes the following contents.

[0043] Such as figure 1 as shown, figure 1 It is the structural formula of n-butanol-2-O-(L-pyroglutamic acid-N-6-)-α-D-fructofuranoside, wherein, n-butanol-2-O-(L-pyroglutamic acid Amino acid-N-6-)-α-D-fructofuranoside C1 and C4 large groups on the fructose are located on both sides, that is, the glycosidic bond is α-type, that is, n-butanol-2-O-( L-pyroglutamic acid-N-6-)-α-D-fructofuranoside is referred to as L-pyroglutamic acid α.

[0044] Such as figure 2 as shown, figure 2 It...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention discloses a new application of n-butanol-2-O-(L-pyroglutamic acid-N-6-)-α-D-fructofuranoside, including its use in the treatment of Alzheimer's disease Application, application in neuron cell proliferation, application in improving learning memory and cognitive ability, application in inhibiting AchE activity, increasing ChAT and Ach content. The spatial configuration of L-pyroglutamic acid α in the present invention enables it to be combined with muscarinic receptor M3, and after L-pyroglutamic acid α is combined with muscarinic receptor M3, Alzheimer's Ach in the brains of patients with silent disease is retained, thereby increasing the content of Ach, while L-pyroglutamic acid β cannot bind to the muscarinic receptor M3, which also shows that L-pyroglutamic acid α has a better The anti-AD effect of the present invention provides an effective basis for L-pyroglutamic acid α anti-AD through molecular biology, thereby providing a new idea for the research of developing anti-AD drugs.

Description

technical field [0001] The invention relates to a new application of n-butanol-2-O-(L-pyroglutamic acid-N-6-)-α-D-fructofuranoside, belonging to the technical field of pharmacy. Background technique [0002] Alzheimer's disease (AD) is a neurodegenerative disease with insidious onset and progressive development. Clinically, it is characterized by comprehensive dementia such as memory impairment, aphasia, apraxia, agnosia, impairment of visuospatial skills, executive dysfunction, and personality and behavior changes. The etiology is still unknown. Those with onset before the age of 65 are called Alzheimer's disease; those with onset after the age of 65 are called senile dementia. [0003] At present, there are 5 anti-AD drugs approved for marketing in the world, namely donepezil, rivastigmine, galantamine, memantine, and donepezil+memantine compound preparations. Mechanisms to improve AD symptoms do not delay disease progression. [0004] In addition, the research on the m...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/7056A61P25/28
CPCA61K31/7056A61P25/28
Inventor 雷霞李冰雷双媛张正一张子涵王来
Owner HEILONGJIANG UNIV OF CHINESE MEDICINE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products